Clinical trials: Human Papillomavirus-Related Cervical Carcinoma
- Condition Human Papillomavirus-Related Cervical Carcinoma
- Age group Children (under 18)
- Has posted results yes
Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ
A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)
This study is designed to evaluate the immunogenicity, safety, and tolerability of Gardasil® (quadrivalent human papillomavirus [qHPV] vaccine, V501) in Chinese girls aged 9-19 years and young women aged 20-26 years.
- Trial name
- NCT03493542
- Testing
- V501
- Where
- China
- Volunteers
- 766 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papillomavirus-Related Cervical Carcinoma
Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial
This phase IIIb trial compares a single dose of the Cervarix vaccine in girls to 3 doses of the Gardasil vaccine in young women for the prevention of human papillomavirus (HPV) infection.
- Trial name
- PRIMAVERA (NCT03728881)
- Testing
- Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine, Recombinant Human Papillomavirus Bivalent Vaccine
- Where
- Costa Rica
- Volunteers
- 1,240 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)